Q1FY22 Earnings Presentation

8 Strides 8 US business impacted by significant price erosion and drop in prescriptions Financial Performance (*/$M) QUARTER ON QUARTER * 4,273 $58 558 * 3,016 $41 YEAR ON YEAR 3,738 $50 * 3,016 $41 OQ1 FY21 0Q1FY22 DQ4FY21 DQ1FY22 >>> - 29% QoQ >>> - 19% YoY YoY comparison in INR reported Business Updates Revenues from the US for Q1FY22 stood at *3,016m ($41m), down 19% YoY, representing 44% of consolidated revenues for Q1FY22 Fewer prescriptions seen with acute portfolio being the most impacted Higher inventory in the market combined with lower prescriptions rates has led to a higher competitive intensity Witnessed double digit price erosion in our portfolio inline with market trends due to heightened competitive intensity New product launches of Q4FY21 have not played out to plan as they witnessed steep price erosion in the current quarter Near Term Outlook Adjusting for overlapping products, our portfolio of 100 approved products will more than double with the acquired basket and will help optimize our future R&D investments Focus to shift towards faster commercialization by enabling 5-6 new product launches every quarter from the combined portfolio With new product launches from the combined portfolio, we remain confident of a bounce back during H2FY22 We expect to end the year with a 10-15% revenue growth over US$ 215m reported in the US for FY21

View entire presentation